Novo Nordisk Bets on AI and Subscriptions to Counter a Steep Slide

Novo Nordisk shares surge as the firm partners with OpenAI to accelerate drug development and expands Wegovy subscription models in the US to boost patient loyalty.

Novo Nordisk shares rallied over 7% last week, a notable gain for a stock still trading roughly 50% below its record high from last June. The jump, closing Friday at €34.47, reflects investor optimism around a new strategic playbook from the Danish pharmaceutical giant. Faced with intensifying competition in the weight-loss drug market, the company is deploying artificial intelligence and revamped commercial models in a bid to regain momentum.

The cornerstone of this push is a newly announced partnership with OpenAI. Novo Nordisk plans to fully integrate the tech firm's generative AI models into its global operations by the end of 2026. The objective is to accelerate drug development by analyzing complex biological datasets faster, significantly shortening the timeline from initial research to clinical trials. The company is launching immediate pilot programs in R&D, manufacturing, and sales, alongside a large-scale internal training initiative for its workforce.

On the commercial front, the company is adjusting its approach for its blockbuster drug Wegovy in the key U.S. market. To build long-term patient loyalty and counter cheaper rival products, Novo Nordisk is expanding a multi-tiered subscription model. Available through telehealth partners like WeightWatchers and Ro, the program offers the injections to self-payers for between $249 and $329 per month. Early data from these partners reportedly shows rising sign-up rates.

Simultaneously, the company is rolling out a higher-dose version of the drug, Wegovy HD (Semaglutid 7.2 mg), now available in over 70,000 U.S. pharmacies. Clinical data provides a supportive narrative: in the 72-week STEP-UP study, patients on the new highest dose lost an average of 20.7% of their body weight, compared to 17.5% on the previous 2.4 mg dose. The list price for self-payers is $399 monthly, though privately insured patients may pay as little as $25.

These strategic moves coincide with a period of internal restructuring and financial support for the share price. After reducing its workforce by approximately 10% in 2025, Novo Nordisk has hired around 2,000 new employees this year, with about 1,400 already onboard, focusing on production, research, and commercial operations. Furthermore, an ongoing share buyback program has seen nearly 11 million B-shares repurchased since February at an average price of around 257 Danish kroner, for a total transaction volume of approximately DKK 2.8 billion. The total program is authorized for up to DKK 15 billion.

Despite the recent share price uplift, significant challenges remain. The stock's Relative Strength Index (RSI) sits at 25, technically indicating it is deeply oversold, and Friday's close was about 21% below its 200-day moving average. Analyst sentiment is cautious; BMO Capital lowered its price target to $36 on April 14, citing concerns that first-quarter revenue from the oral Wegovy pill may disappoint. Jefferies maintains a neutral rating.

The company's own guidance for 2026 forecasts a revenue decline of 5% to 13%, factoring in pricing pressure and political headwinds in the United States. A pivotal moment will arrive in mid-2026 when Medicare is expected to decide on cost coverage for obesity medications. The sustainability of the current share price recovery will likely be tested sooner, however, by first-quarter earnings that will reveal the initial demand for Wegovy HD and the early impact of the new commercial strategies.